2022-500100-21-01招募中2 期
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
Oslo University Hospital Hf21 个研究点 分布在 4 个国家目标入组 80 人开始时间: 2023年2月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 21
- 主要终点
- Progression free survival (within an observation time of a minimum of two years and a maximum of four years depending on the timepoint of patient inclusion in the trial
研究概览
简要总结
The primary objective is to investigate the efficacy of 2nd line treatment with subcutaneous mosunetuzumab monotherapy in FL with refractory disease, progression or relapse of disease within 24 months of starting 1st line treatment (POD24).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent according to ICH-GCP guidelines
- •Age ≥ 18 years
- •Follicular lymphoma grade 1-3a with a current relapse or progression within 24 months of starting 1st line treatment or refractory to 1st line treatment (POD24), more specifically: a. Documented current relapse or progression of FL within 24 months of starting first line treatment containing a monospecific anti-CD20 antibody (such as rituximab or obinutuzumab with or without chemotherapy, small molecular inhibitors or immunomodulating agents such as lenalidomide). b. Alternatively, current lack of response/refractoriness to first line treatment, i.e., no objective response or documented progression within 6 months following at least four cycles of monotherapy with a monospecific anti-CD20 antibody (such as rituximab 375mg/m2 iv or 1400 mg SC or equal) or following at least three cycles of a monospecific anti CD20 antibody combined with chemotherapy, small molecular inhibitors or immunomodulating agents such as lenalidomide. c. Received one prior treatment line of systemic therapy. d. If the POD24 event was diagnosed more than three months ago, then study inclusion has been clarified with the coordinating investigator. e. Patients may have received localized radiotherapy previously. Patients may have received localized radiotherapy previously. If the radiotherapy was recent, the patient must have at least one progressive and measurable lesion outside the radiation field.
- •At least one two-dimensionally measurable lesion with a longest diameter >15mm.
- •WHO performance status 0-
- •Patients with reduced WHO performance status (> 2) can be considered if reduction in performance is caused by the lymphoma as determined by the investigator.
排除标准
- •Received 2 or more previous treatment lines.
- •Impaired liver function not caused by lymphoma, defined as serum total bilirubin ≥ 1.5 x ULN (unless elevated due to Gilbert’s syndrome) or serum ALT and AST ˃ 3 x ULN
- •Impaired renal function not caused by lymphoma, defined as calculated creatinine clearance <= 40 ml/minute
- •Grade 3b FL.
- •Other major organ dysfunction not caused by lymphoma
- •Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension.
- •HIV positivity: Subjects that are on HIV-treatment with undetectable HIV-RNA and CD4-counts above 200 will be eligible.
- •Women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for three months after completion of treatment.
- •Hepatitis B (HBV) or hepatitis C (HCV) infection: Subjects with a previous hepatitis B infection will be eligible if they are negative for HBV-DNA; these subjects must be given prophylactic antiviral therapy. Subjects with a previous HCV infection will be eligible if they are negative for HCV-RNA.
- •Known or suspected chronic active Epstein-Barr virus (EBV) infection.
- •Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within two weeks prior to the first dose of mosunetuzumab.
- •Other current severe medical problems or expected survival of less than approximately five years for non-lymphoma reasons.
- •Administration of live vaccines within four weeks of the first dose of mosunetuzumab or anticipation that live vaccine will be required during the study.
- •History of severe allergic or anaphylactic reactions to chimeric, human, or humanized antibodies, or fusion proteins.
- •Known or suspected hemophagocytic syndrome.
- •Prior allogeneic hematopoietic stem cell transplant.
- •Active severe infection.
- •Current or previous other malignancy within three years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other non-invasive or indolent malignancy without sponsor approval.
- •CD20-negative lymphoma
- •Psychiatric disorder or dementia which make the patient unable to give an informed consent and/or adhere to the schedule.
- •Pregnancy or breast-feeding.
- •CNS involvement (current or previous)
- •Impaired bone marrow function (neutrophils < 1.0 x 10^9/L or platelets < 50 x 10^9/L) unless due to lymphoma involvement
- •Severe cardiac disease: impaired cardiac function (NYHA class III or IV), myocardial infarction within the last 6 months, unstable arrythmias and/or unstable angina pectoris.
结局指标
主要结局
Progression free survival (within an observation time of a minimum of two years and a maximum of four years depending on the timepoint of patient inclusion in the trial
Progression free survival (within an observation time of a minimum of two years and a maximum of four years depending on the timepoint of patient inclusion in the trial
次要结局
- Resource usage during treatment such as the rate of hospitalizations and duration of hospitalizations due to mosunetuzumab treatment and/or AEs and the number of out-patient consultations due to mosunetuzumab treatment and/or AEs.
- Quality of life during and after treatment (as measured by EORTC QLQ-C30 and by EQ-5D).
- Complete response rate (CRR) by FDG-PET-CT to 8 cycles of mosunetuzumab
- Overall response rate (ORR) by FDG-PET-CT to 8 cycles of mosunetuzumab
- Best CRR and ORR (by CT) to all administered cycles of mosunetuzumab
- CRR and ORR (by CT) at 30 months after start of treatment
- Duration of response (DOR) from the first occurrence of documented response by FDG-PET-CT to disease progression or death of any cause.
- Time to new lymphoma treatment (from inclusion to the start of treatment other than mosunetuzumab due to progression of disease or to death of any cause).
- PFS stratified by type of first line treatment (R monotherapy versus R combined with chemotherapy or other agents).
- PFS by FDG-PET-CT response groups according to the 2014 Lugano Classification (from inclusion to the first occurrence of disease progression as determined by investigator or death from any cause).
- Overall survival (OS) from inclusion to death of any cause.
- Safety and tolerability of treatment, as the percentage of patients with adverse events (AEs) and the rate of dropout due to AEs.
- Histology at relapse or progression occurring after or during study treatment.
- Rate of transformation to higher-grade lymphoma.
研究者
Coordinating Investigator
Scientific
Oslo University Hospital Hf
研究点 (21)
Loading locations...
相似试验
招募中
2 期
A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus with or without Active Lupus Nephritis2024-519930-22-00F. Hoffmann-La Roche AG5
招募中
不适用
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).NCT07278921Andrés José Maria Ferreri25
进行中（未招募）
2 期
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesNon-Hodgkin LymphomaNCT05207670Genentech, Inc.320
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome2023-505140-19-00F. Hoffmann-La Roche AG26
招募中
1 期
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)Follicular lymphomaMedDRA version: 21.1Level: PTClassification code: 10016905Term: Follicle centre lymphoma follicular grade I II III recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061170Term: Follicle centre lymphoma follicular grade I II III Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10067070Term: Follicular B-cell non-Hodgkin's lymphoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10016904Term: Follicle centre lymphoma follicular grade I II III NOS Class: 10029104CTIS2022-500100-21-01Oslo University Hospital Hf80